← Leaderboards
James E Loyd
Vanderbilt University
$19,105,238
Attributed
$20,848,844
Total exposure
16
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$47,974,463 · 18
By mechanism
P01$42,251,315 · 10
R01$4,745,079 · 2
U10$974,444 · 1
M01$3,625 · 5
Top collaborators
- Anne K Kenworthy7 shared
- Anna R Hemnes2 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Timothy S Blackwell$28,109,454
- Eric Douglas Austin$6,099,747
- Laurence J Zwiebel$9,792,749
- Anna L Means$3,046,722
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungSignal TransductionEffective TherapyMolecularFuturePulmonary Arterial HypertensionDefectClinical ResearchPhenotypeProgramsHormonalBaseMetabolicMutationGeneticFamilyPathogenesisHuman SubjectBlood VesselsCharacteristicsPulmonary HypertensionCohortResourcesMouse Model
Grant awards (81)
Sex Hormones in Pulmonary Arterial Hypertension$626,833
P01 · FY2021 · HL · contact PI
Administrative Core$133,245
P01 · FY2021 · HL · contact PI
Sex Hormones in Pulmonary Arterial Hypertension$600,443
P01 · FY2020 · HL · contact PI
Clinical Ascertainment and Phenotyping$418,550
P01 · FY2020 · HL · contact PI
Administrative Core$133,246
P01 · FY2020 · HL · contact PI
Sex Hormones in Pulmonary Arterial Hypertension$600,443
P01 · FY2019 · HL · contact PI
Clinical Ascertainment and Phenotyping$415,971
P01 · FY2019 · HL · contact PI
Administrative Core$133,246
P01 · FY2019 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$1,654,352
P01 · FY2018 · HL · contact PI
Sex Hormones in Pulmonary Arterial Hypertension$601,064
P01 · FY2018 · HL · contact PI
Clinical Ascertainment and Phenotyping$378,275
P01 · FY2018 · HL · contact PI
Administrative Core$133,246
P01 · FY2018 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$1,705,535
P01 · FY2017 · HL · contact PI
Sex Hormones in Pulmonary Arterial Hypertension$590,009
P01 · FY2017 · HL · contact PI
Clinical Ascertainment and Phenotyping$400,742
P01 · FY2017 · HL · contact PI
Administrative Core$140,699
P01 · FY2017 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$2,759,549
P01 · FY2016 · HL · contact PI
Sex Hormones in Pulmonarv Arterial Hypertension$833,441
P01 · FY2016 · HL · contact PI
Caveolar Defects Underlie the Genetic Origins of PAH$644,338
R01 · FY2016 · HL · contact PI
Clinical Ascertainment and Phenotyping$409,148
P01 · FY2016 · HL · contact PI
Administrative Core$203,660
P01 · FY2016 · HL · contact PI
Caveolar Defects Underlie the Genetic Origins of PAH$24,402
R01 · FY2016 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$2,016,553
P01 · FY2015 · HL · contact PI
Sex Hormones in Pulmonarv Arterial Hypertension$822,551
P01 · FY2015 · HL · contact PI
Caveolar Defects Underlie the Genetic Origins of PAH$701,029
R01 · FY2015 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$675,432
P01 · FY2015 · HL · contact PI
Sex Hormones in Pulmonarv Arterial Hypertension$207,027
P01 · FY2015 · HL · contact PI
Administrative Core$200,604
P01 · FY2015 · HL · contact PI
Administrative Core$50,588
P01 · FY2015 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$2,632,685
P01 · FY2014 · HL · contact PI
Sex Hormones in Pulmonarv Arterial Hypertension$748,990
P01 · FY2014 · HL · contact PI
Caveolar Defects Underlie the Genetic Origins of PAH$710,806
R01 · FY2014 · HL · contact PI
Clinical Ascertainment and Phenotype$375,194
P01 · FY2014 · HL · contact PI
Administrative Core$199,585
P01 · FY2014 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$100,000
P01 · FY2014 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$2,661,144
P01 · FY2013 · HL · contact PI
Sex Hormones in Pulmonarv Arterial Hypertension$833,679
P01 · FY2013 · HL · contact PI
Caveolar Defects Underlie the Genetic Origins of PAH$701,513
R01 · FY2013 · HL · contact PI
Clinical Ascertainment and Phenotype$364,996
P01 · FY2013 · HL · contact PI
Administrative Core$193,883
P01 · FY2013 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$96,615
P01 · FY2013 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$2,667,336
P01 · FY2012 · HL · contact PI
Sex Hormones in Pulmonarv Arterial Hypertension$728,233
P01 · FY2012 · HL · contact PI
Caveolar Defects Underlie the Genetic Origins of PAH$685,585
R01 · FY2012 · HL · contact PI
Clinical Ascertainment and Phenotype$387,335
P01 · FY2012 · HL · contact PI
Administrative Core$213,020
P01 · FY2012 · HL · contact PI
Caveolar Defects Underlie the Genetic Origins of PAH$19,539
R01 · FY2012 · HL · contact PI
Clinical Ascertainment and Phenotype$386,326
P01 · FY2011 · HL · contact PI
Clinical Ascertainment and Phenotype$422,135
P01 · FY2010 · HL · contact PI
IPF Clinical Trial Center at Vanderbilt$204,767
U10 · FY2009 · HL · contact PI
IPF Clinical Trial Center at Vanderbilt$194,828
U10 · FY2008 · HL · contact PI
Genetic and Environmental Pathogenesis of Primary Pulmonary Hypertension$2,002,156
P01 · FY2007 · HL · contact PI
THE MOLECULAR BASIS OF FAMILIAL AND SPORADIC PPH$529,241
P01 · FY2007 · HL · contact PI
IPF Clinical Trial Center at Vanderbilt$192,907
U10 · FY2007 · HL · contact PI
Genetic and Environmental Pathogenesis of PPH$2,045,111
P01 · FY2006 · HL · contact PI
THE MOLECULAR BASIS OF FAMILIAL AND SPORADIC PPH$532,052
P01 · FY2006 · HL · contact PI
IPF Clinical Trial Center at Vanderbilt$192,150
U10 · FY2006 · HL · contact PI
Genetic and Environmental Pathogenesis of PPH$2,086,971
P01 · FY2005 · HL
THE MOLECULAR BASIS OF FAMILIAL AND SPORADIC PPH$517,590
P01 · FY2005 · HL
IPF Clinical Trial Center at Vanderbilt$189,792
U10 · FY2005 · HL
MOLECULAR BASIS OF PRIMARY PULMONARY HYPERTENSION (PPH)$1,382
M01 · FY2005 · RR
Genetic and Environmental Pathogenesis of PPH$1,982,186
P01 · FY2004 · HL
THE MOLECULAR BASIS OF FAMILIAL AND SPORADIC PPH$479,561
P01 · FY2004 · HL
CORE A-- ADMINISTRATIVE CORE$180,845
P01 · FY2004 · HL
Molecular Basis of Primary Pulmonary Hypertension (PPH)$1,651
M01 · FY2004 · RR
Genetic and Environmental Pathogenesis of PPH$2,039,994
P01 · FY2003 · HL
PULMONARY HYPERTENSION--MECHANISMS AND FAMILY REGISTRY$158,814
R01 · FY2003 · HL
PULMONARY HYPERTENSION--MECHANISMS AND FAMILY REGISTRY$373,978
R01 · FY2002 · HL
AVONEX IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS$0
M01 · FY2002 · RR
SDZ RAD IN STABLE LUNG TRANSPLANT RECIPIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2002 · RR
PULMONARY HYPERTENSION--MECHANISMS AND FAMILY REGISTRY$366,809
R01 · FY2001 · HL
SDZ RAD IN STABLE LUNG TRANSPLANT RECIPIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2001 · RR
AVONEX IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS$0
M01 · FY2001 · RR
SDZ RAD IN STABLE LUNG TRANSPLANT RECIPIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2001 · RR
AVONEX IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS$0
M01 · FY2001 · RR
AVONEX IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS$0
M01 · FY2001 · RR
SDZ RAD IN STABLE LUNG TRANSPLANT RECIPIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2001 · RR
PULMONARY HYPERTENSION--MECHANISMS AND FAMILY REGISTRY$358,266
R01 · FY2000 · HL
CHRONIC FLOLAN (EPOPROSTERNOL SODIUM) INJECTION/INFUSION IN PPH PATIENTS$592
M01 · FY2000 · RR
SDZ RAD IN STABLE LUNG TRANSPLANT RECIPIENTS WITH CYSTIC FIBROSIS$0
M01 · FY2000 · RR
AVONEX IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS$0
M01 · FY2000 · RR